{"gene":"XRCC1","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":1997,"finding":"The C-terminal 96 amino acids of XRCC1 are necessary and sufficient for direct interaction with DNA ligase III (103 kDa form), and the C-terminal 148 amino acids of DNA ligase III contain the binding site for XRCC1. The alternatively spliced 96 kDa testis form of DNA ligase III lacks this interaction, indicating only the 103 kDa isoform partners with XRCC1 in base excision repair.","method":"Far Western analysis and affinity precipitation with subcloned XRCC1 and DNA ligase III fragments; antipeptide antibodies to distinguish isoforms","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro domain-mapping reconstitution with multiple truncation fragments and orthogonal methods (far Western + affinity precipitation + antibody discrimination of isoforms)","pmids":["9136882"],"is_preprint":false},{"year":2004,"finding":"XRCC1 co-localizes with PCNA at DNA replication foci exclusively in S phase of undamaged HeLa cells, physically interacts with PCNA in vivo (shown by FRET and co-immunoprecipitation), and the interaction is mediated by XRCC1 residues 166–310 in vitro, suggesting XRCC1 is sequestered to replication factories via PCNA to facilitate single-strand break repair in S phase.","method":"Fluorescence co-localization, FRET analysis, co-immunoprecipitation, in vitro biochemical assay with XRCC1 truncation fragments","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus FRET plus in vitro domain mapping, single lab, multiple orthogonal methods","pmids":["15107487"],"is_preprint":false},{"year":2006,"finding":"XRCC1 is phosphorylated at serine 371 by the DNA-PK complex (interacting via the BRCT1 domain) in response to ionizing radiation. This phosphorylation causes XRCC1 dimer dissociation. The non-phosphorylable S371L mutant fails to fully rescue DSB repair defects in XRCC1-deficient EM9 cells, establishing a functional role for DNA-PK-mediated XRCC1 phosphorylation in DSB repair. XRCC1 also strongly stimulates DNA-PK-mediated phosphorylation of p53-Ser15.","method":"GST-BRCT1 pulldown followed by mass spectrometry; phosphorylation assays; XRCC1 mutant (S371D and S371L) rescue of EM9 cells; in vitro kinase assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assay with mutagenesis, pulldown-MS identification of kinase, functional rescue experiment, multiple orthogonal methods in one study","pmids":["16397295"],"is_preprint":false},{"year":2007,"finding":"XRCC1 stimulates polynucleotide kinase (PNK) activity by two mechanisms: (1) enhancing PNK's ability to discriminate between 5'-OH and 5'-phosphate termini at strand breaks, and (2) displacing PNK from the phosphorylated DNA product, thereby accelerating PNK turnover.","method":"Fluorescence binding assays, fluorescence anisotropy, kinetic assays at limiting enzyme concentration with XRCC1 and PNK on defined DNA substrates","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro system with defined DNA substrates, multiple fluorescence methods, mechanistic discrimination of two activities, single lab","pmids":["17650498"],"is_preprint":false},{"year":2010,"finding":"Casein kinase 2 (CK2) is the major kinase responsible for XRCC1 phosphorylation in human cell extracts. CK2-mediated phosphorylation is required for stability of the XRCC1–DNA ligase IIIα complex; mutation of CK2 phosphorylation sites in XRCC1 destabilizes this complex. siRNA knockdown of CK2 reduces XRCC1 phosphorylation and stability, decreases Lig III levels, and leads to accumulation of DNA strand breaks.","method":"Unbiased kinase activity assay in cell extracts; site-directed mutagenesis of CK2 phosphorylation sites; siRNA knockdown of CK2; comet assay for strand breaks","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — unbiased biochemical identification of kinase, mutagenesis validation, siRNA knockdown with functional readout, multiple orthogonal methods","pmids":["20471329"],"is_preprint":false},{"year":2004,"finding":"Purified full-length human XRCC1 exists as a monomer at low concentrations and forms a dimer at higher concentrations (Kd ~570 nM). It preferentially binds DNA containing single-strand breaks with gaps ≤1 nucleotide (Kd 34–65 nM) compared to 5-nucleotide gaps, intact duplex, or single-stranded DNA (Kd ~215–260 nM), indicating selective recognition of short-gap SSBs.","method":"Sedimentation equilibrium ultracentrifugation, fluorescence titration binding assays with defined model DNA substrates","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — purified recombinant protein, biophysical reconstitution with multiple defined substrates, quantitative binding constants determined","pmids":["15610045"],"is_preprint":false},{"year":2015,"finding":"The phosphate-binding pocket within XRCC1's central BRCT1 domain is required for selective binding to poly(ADP-ribose) (PAR) at low ADP-ribosylation levels and promotes interaction with cellular PARP1. This pocket is required for XRCC1 recruitment to UVA laser, H2O2 damage sites, and sub-nuclear PCNA foci, and is essential for XRCC1-dependent acceleration of SSBR, BER, and cell survival after DNA damage.","method":"Mutagenesis of phosphate-binding pocket residues; PAR binding assays; EGFP-XRCC1 live-cell recruitment at laser-induced damage; co-immunoprecipitation with PARP1; clonogenic survival and repair kinetics assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis combined with live-cell imaging, Co-IP, and functional survival assays, multiple orthogonal methods, single lab","pmids":["26130715"],"is_preprint":false},{"year":2014,"finding":"The XRCC1–DNA polymerase β heterodimer is not required for DNA damage response or recruitment to damage sites; instead, heterodimer formation protects Polβ from CHIP-mediated ubiquitylation and degradation. XRCC1 monomer stability is independently protected from CHIP by binding to HSP90. In response to cellular proliferation and DNA damage, HSP90- and proteasome-mediated regulation alters the repair complex architecture.","method":"Co-immunoprecipitation; ubiquitylation assays; HSP90 inhibitor (17-AAG) treatment; siRNA knockdown; live-cell imaging of DNA damage response","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitylation assay, pharmacological inhibition, and knockdown with functional readout; multiple orthogonal methods in one study","pmids":["25423885"],"is_preprint":false},{"year":2016,"finding":"Biallelic XRCC1 mutations in patients cause elevated PARP1 hyperactivation (elevated protein ADP-ribosylation) and single-strand break repair deficiency. Genetic deletion of Parp1 in Xrcc1-deficient mice rescues normal cerebellar ADP-ribose levels, reduces cerebellar neuron loss, and reduces ataxia, establishing that PARP1 hyperactivation caused by loss of XRCC1 is the mechanistic driver of cerebellar neuropathology.","method":"Patient-derived fibroblast analysis; Xrcc1/Parp1 double-knockout mouse model; ADP-ribosylation quantification; cerebellar neuron counting; behavioral ataxia scoring","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in mouse KO model plus patient cell analysis, replicated across multiple experimental systems","pmids":["28002403"],"is_preprint":false},{"year":2021,"finding":"XRCC1 assembles complexes containing DNA polymerase β and DNA ligase III that prevent excessive PARP1 engagement and activity during BER. In XRCC1-deficient cells, PARP1 becomes 'trapped' on BER intermediates (similar to PARP inhibitor trapping), blocking access of repair enzymes such as Polβ. Deletion of PARP1 rescues BER and resistance to base damage in XRCC1-knockout cells.","method":"XRCC1-knockout cell lines; PARP1 trapping assays; BER intermediate accessibility assays; PARP1 deletion epistasis; patient fibroblast validation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO epistasis, PARP trapping assays, patient cell validation, multiple orthogonal methods replicated across cell types","pmids":["34102106"],"is_preprint":false},{"year":2021,"finding":"XRCC1 loss causes failure to recover transcription after DNA base damage due to aberrant/excessive PARP1 activity during BER. This aberrant PARP1 activity promotes excessive recruitment of the ubiquitin protease USP3, which reduces monoubiquitinated histones required for normal transcriptional regulation. Inhibition or deletion of PARP1 or USP3 restores transcriptional recovery in XRCC1-deficient cells.","method":"XRCC1-knockout human cells and Xrcc1-/- mouse neurons; transcription recovery assays; USP3 inhibition/deletion; histone ubiquitination measurement; PARP1 inhibition rescue","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with mechanistic pathway dissection through multiple orthogonal interventions (PARP1 inhibition, USP3 deletion, histone ubiquitination measurement), validated in neurons and patient fibroblasts","pmids":["34811483"],"is_preprint":false},{"year":2005,"finding":"XRCC1-deficient cell extracts have normal base excision activity for 8-oxoguanine, 5-hydroxycytosine, ethenoadenine, and uracil; normal abasic site incision; and normal gap-filling. However, a ~2–4-fold reduction in nick ligation activity is observed, indicating that the primary biochemical defect of XRCC1 deficiency is at the ligation step of BER/SSBR.","method":"Whole-cell extract BER assays; DNA damage measurement (8-OH-dG levels); nick ligation assays with defined substrates in XRCC1-deficient (EM9) versus wild-type CHO extracts","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic in vitro reconstitution assays covering each BER step with defined substrates; multiple lesion types tested; single lab","pmids":["16245950"],"is_preprint":false},{"year":2008,"finding":"E2F1 transcription factor directly activates XRCC1 promoter transcription via E2F1 binding sites in the promoter. Ectopic wild-type E2F1 (but not a DNA-binding mutant) increases endogenous XRCC1 expression. DNA damage stimulates XRCC1 expression in E2F1+/+ but not E2F1-/- MEFs, and E2F1-/- MEFs show attenuated DNA repair after MMS treatment.","method":"Luciferase reporter assays with XRCC1 promoter deletions; conditional E2F1 expression; E2F1-/- MEF analysis; promoter E2F1 binding site deletion mutagenesis; MMS survival and repair assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — promoter reporter mutagenesis, genetic KO MEF rescue, multiple orthogonal methods in one study","pmids":["18348985"],"is_preprint":false},{"year":2011,"finding":"Genetic inactivation of LIG3 (DNA Ligase III) specifically in the nervous system reveals that LIG3 function is central to mitochondrial DNA maintenance rather than nuclear SSBR, in contrast to XRCC1. The data indicate that DNA Ligase 1 (not LIG3) is the main DNA ligase for XRCC1-mediated nuclear DNA repair.","method":"Conditional tissue-specific knockout mouse models for XRCC1 and LIG3 in developing nervous system; phenotypic comparison; mitochondrial DNA integrity analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via conditional KO mouse models with defined phenotypic readouts, comparison of XRCC1 and LIG3 knockouts","pmids":["21636980"],"is_preprint":false},{"year":2016,"finding":"XRCC1 is an indispensable mediator of muscle differentiation. Caspase-triggered XRCC1 repair foci form rapidly within differentiating myonuclei and then dissipate. Skeletal myoblast-specific deletion of Xrcc1 does not affect cell growth but causes perinatal lethality with sustained DNA damage and impaired myofiber development, demonstrating a temporally required DNA repair function for terminal differentiation.","method":"Conditional Xrcc1 deletion in skeletal myoblasts; live-cell XRCC1 repair foci imaging; perinatal lethality and myofiber histology; DNA damage markers","journal":"Cell discovery","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific developmental phenotype, live imaging of repair foci, functional rescue experiments implied by distinct phenotypic characterization","pmids":["27462438"],"is_preprint":false},{"year":2019,"finding":"SIRT1 binds and deacetylates XRCC1 at lysine residues K260, K298, and K431, preventing β-TrCP E3 ligase-mediated poly-ubiquitination and proteasomal degradation of XRCC1. Mutations of these three lysine sites abrogate interaction with β-TrCP and prolong XRCC1 protein half-life, conferring chemoresistance.","method":"Co-immunoprecipitation; SIRT1 knockdown/inhibition; ubiquitination assays; site-directed mutagenesis of XRCC1 lysine residues; cycloheximide chase for protein half-life","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct deacetylation site identified by mutagenesis, ubiquitination assays, Co-IP, and half-life measurements; multiple orthogonal methods","pmids":["31043584"],"is_preprint":false},{"year":2018,"finding":"KDM5B demethylase demethylates H3K4 at DNA damage sites and facilitates recruitment of XRCC1 to γH2AX-marked damage. KDM5B knockdown increases H3K4 methylation and blocks XRCC1 localization to DNA damage sites. HSP90 protects KDM5B from ubiquitin-dependent proteasomal degradation, and the HSP90–KDM5B–XRCC1 axis mediates cisplatin resistance.","method":"KDM5B knockdown/overexpression; co-immunoprecipitation (HSP90–KDM5B); co-localization of XRCC1 with γH2AX; H3K4 methylation analysis; JIB-04 and 17-AAG pharmacological inhibition; mass spectrometry","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and co-localization with KDM5B manipulation, but the direct mechanistic link between H3K4 demethylation and XRCC1 recruitment is inferred from co-localization rather than direct biochemical reconstitution","pmids":["29989047"],"is_preprint":false},{"year":2019,"finding":"XRCC1 contains a central DNA binding domain (CDB, residues 219–415) encompassing the BRCT1 domain. Unlike the N-terminal domain, the CDB binds DNA without specificity for nicked or gapped substrates. Alanine substitutions in the CDB disrupt DNA binding in vitro and reduce XRCC1 retention (but not initial recruitment) at DNA damage sites, and reduced retention is associated with an increased rate of repair.","method":"XRCC1 domain truncation/mutagenesis; in vitro DNA binding assays; laser microirradiation with live-cell fluorescence imaging of XRCC1 accumulation kinetics","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro mutagenesis combined with live-cell imaging of recruitment and retention, domain-specific functional dissection","pmids":["30816207"],"is_preprint":false},{"year":2018,"finding":"XRCC1 residues 166–436 bind tightly to PNKP and DNA and efficiently activate PNKP's kinase activity. Cancer-associated SNP variants R194W and R280H in this fragment show considerably weaker PNKP interaction and severely reduced stimulation of PNKP kinase activity. In cells, these XRCC1 variants show reduced ability to recruit PNKP to laser-microirradiation-induced DNA damage sites.","method":"Domain binding assays; PNKP kinase activity assays with XRCC1 fragments; laser microirradiation with fluorescence microscopy of PNKP recruitment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assay with domain mapping plus live-cell PNKP recruitment imaging; SNP variant functional characterization","pmids":["30446622"],"is_preprint":false},{"year":2017,"finding":"CK2-mediated phosphorylation of XRCC1 at multiple consensus sites is required for PNKP binding to XRCC1 and efficient PNKP recruitment to DNA damage. A phosphorylation mutant XRCC1 that eliminates PNKP binding fails to support efficient PNKP recruitment to microirradiation-induced damage. However, cells expressing this PNKP interaction mutant of XRCC1 show marked reversal of CPT hypersensitivity, revealing XRCC1-dependent repair that does not require phosphorylation-dependent PNKP recruitment.","method":"Stable expression of XRCC1 phosphorylation mutant in Xrcc1-/- mouse fibroblasts; PNKP-GFP microirradiation recruitment assay; clonogenic survival after CPT and H2O2","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic complementation in Xrcc1-/- cells with phosphorylation mutant, live-cell fluorescence imaging, survival assays; multiple orthogonal methods","pmids":["29100039"],"is_preprint":false},{"year":2020,"finding":"After replication stress, XRCC1 forms an active repair complex with POLQ and MRE11 that supports alternative end-joining (alt-EJ/MMEJ) activity in vitro. BRCA2 normally limits XRCC1 recruitment and complex formation to suppress alt-EJ at stalled forks. In BRCA2-deficient cells, XRCC1 enables replication completion via MRE11-dependent fork resection and restart at the expense of increased genome instability.","method":"In vitro alt-EJ reconstitution assay with XRCC1, POLQ, MRE11; Co-IP of XRCC1 with POLQ and MRE11; BRCA2 depletion in combination with XRCC1 depletion; replication fork restart and chromosome aberration assays","journal":"NAR cancer","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution of complex plus Co-IP and genetic epistasis, single lab, novel pathway context","pmids":["32776008"],"is_preprint":false},{"year":2022,"finding":"PARP1 and XRCC1 exhibit a reciprocal relationship: recruitment of either protein to DNA damage sites is impeded in the absence of the other in HeLa cells. In XRCC1 KO cells, hypersensitivity to CPT and impaired DNA repair can be partially rescued by additional deletion of PARP1, confirming that aberrant PARP1 activity drives toxicity in XRCC1-deficient cells.","method":"PARP1 KO, XRCC1 KO, and double KO HeLa cells; live-cell imaging of damage recruitment; NAD+ measurements; clonogenic survival; cell cycle and cell death analysis; comet assay","journal":"Cell biology and toxicology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple genetic KO combinations with diverse functional readouts; reciprocal recruitment established by live imaging; single lab","pmids":["35778544"],"is_preprint":false},{"year":1992,"finding":"XRCC1 mRNA levels are substantially higher in testis (7–8 fold), ovary (3–4 fold), and brain (4–5 fold) compared to intestine, liver, and spleen, and high XRCC1 protein levels are detected in testis, suggesting a specialized role in DNA processing during meiogenesis and recombination.","method":"Northern blot analysis; tissue-specific mRNA quantification; Western blot for XRCC1 protein in rat tissues","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — tissue-specific expression pattern established by Northern blot and protein detection, replicated in baboon model (PMID 8524362); functional inference from expression pattern","pmids":["1353960"],"is_preprint":false}],"current_model":"XRCC1 functions as a molecular scaffold protein that coordinates DNA single-strand break repair (SSBR) and base excision repair (BER) by recruiting and stimulating multiple enzymatic activities—including polynucleotide kinase (PNK), DNA polymerase β, and DNA ligase IIIα/Ligase I—at break sites, where it is recruited via its BRCT1 domain binding to PARP1-synthesized poly(ADP-ribose) and is regulated by CK2-mediated phosphorylation (required for PNKP recruitment) and DNA-PK-mediated phosphorylation at S371 (required for DSB repair); critically, XRCC1 also acts as an 'anti-trapper' that limits excessive PARP1 engagement on BER intermediates, and loss of XRCC1 leads to toxic PARP1 hyperactivation that suppresses transcription (via USP3/histone ubiquitination) and drives cerebellar neurodegeneration reversible by PARP1 deletion."},"narrative":{"mechanistic_narrative":"XRCC1 is a non-enzymatic scaffold protein that coordinates DNA single-strand break repair (SSBR) and base excision repair (BER) by physically organizing and stimulating the enzymatic machinery at break sites [PMID:9136882, PMID:16245950]. It selectively recognizes short-gap single-strand breaks through dedicated DNA-binding activity, with an N-terminal preference for gaps ≤1 nucleotide and a central BRCT1-containing DNA-binding domain (residues 219–415) that mediates retention rather than initial recruitment [PMID:15610045, PMID:30816207]. XRCC1 is recruited to damage via its BRCT1 phosphate-binding pocket, which binds PARP1-synthesized poly(ADP-ribose) and is required for accumulation at laser-, H2O2-, and replication-associated damage [PMID:26130715]. Once positioned, XRCC1 directly partners with the 103 kDa form of DNA ligase IIIα, DNA polymerase β, and polynucleotide kinase phosphatase (PNKP), stimulating PNKP catalysis by enhancing terminus discrimination and accelerating enzyme turnover [PMID:9136882, PMID:17650498, PMID:30446622]; the principal biochemical consequence of XRCC1 loss is a defect at the ligation step of BER/SSBR [PMID:16245950]. Complex architecture and stability are tuned post-translationally: CK2 phosphorylation maintains the XRCC1–ligase IIIα complex and licenses PNKP recruitment, DNA-PK phosphorylation at S371 dissociates XRCC1 dimers and supports DSB repair, and heterodimer formation plus HSP90 binding protect XRCC1 and Polβ from CHIP-mediated degradation [PMID:16397295, PMID:20471329, PMID:25423885, PMID:29100039]. Beyond catalyzing repair, XRCC1 acts as an anti-trapper that restrains excessive PARP1 engagement on BER intermediates; in its absence PARP1 becomes trapped and hyperactivated, blocking repair-enzyme access, suppressing transcriptional recovery through USP3-driven loss of histone monoubiquitination, and driving cerebellar neurodegeneration that is rescued by PARP1 deletion [PMID:34102106, PMID:34811483, PMID:28002403, PMID:35778544]. Biallelic XRCC1 mutations cause a human SSBR-deficiency syndrome with PARP1 hyperactivation and cerebellar ataxia [PMID:28002403].","teleology":[{"year":1992,"claim":"Established that XRCC1 is expressed at elevated levels in specific tissues, raising the question of where its repair function is most critical.","evidence":"Northern and Western analysis across rat tissues","pmids":["1353960"],"confidence":"Medium","gaps":["Expression pattern alone does not define molecular function","Functional role in meiosis/recombination inferred, not tested"]},{"year":1997,"claim":"Identified the first direct partner of XRCC1, defining it as a scaffold that recruits a ligase rather than acting catalytically itself.","evidence":"Far Western and affinity precipitation with XRCC1 and DNA ligase III truncation fragments, isoform-specific antibodies","pmids":["9136882"],"confidence":"High","gaps":["Did not establish which ligase performs nuclear repair in vivo","Functional consequence of the interaction not measured"]},{"year":2004,"claim":"Showed XRCC1 selectively recognizes short-gap single-strand breaks and is recruited to replication factories via PCNA, linking scaffold function to substrate specificity and S-phase repair.","evidence":"Sedimentation equilibrium and fluorescence titration with defined DNA substrates; FRET, Co-IP, and in vitro domain mapping in HeLa cells","pmids":["15610045","15107487"],"confidence":"High","gaps":["Structural basis of gap-length discrimination not resolved","Physiological contribution of the PCNA interaction to repair not quantified"]},{"year":2006,"claim":"Defined DNA-PK phosphorylation of XRCC1 at S371 as a regulatory switch controlling dimer state and DSB repair, extending XRCC1 function beyond SSBR.","evidence":"BRCT1 pulldown-MS, in vitro kinase assays, S371 mutant rescue of EM9 cells","pmids":["16397295"],"confidence":"High","gaps":["Mechanistic link between dimer dissociation and DSB repair unresolved","Direct DSB substrate engagement not shown"]},{"year":2007,"claim":"Demonstrated XRCC1 mechanistically stimulates PNK by enhancing terminus discrimination and accelerating turnover, showing scaffold activity directly tunes enzyme kinetics.","evidence":"Reconstituted fluorescence binding, anisotropy, and kinetic assays with PNK on defined substrates","pmids":["17650498"],"confidence":"High","gaps":["Domain of XRCC1 mediating stimulation not mapped here","In vivo relevance of turnover acceleration not tested"]},{"year":2005,"claim":"Pinpointed the ligation step as the primary biochemical defect in XRCC1 deficiency, narrowing its essential function within the BER pathway.","evidence":"Stepwise BER reconstitution assays in EM9 versus wild-type CHO extracts","pmids":["16245950"],"confidence":"High","gaps":["Did not identify the responsible ligase in vivo","Whole-extract assay may mask redundant activities"]},{"year":2008,"claim":"Identified E2F1 as a direct transcriptional activator of XRCC1, connecting repair capacity to cell-cycle and damage-responsive gene regulation.","evidence":"Promoter luciferase reporters, E2F1 binding-site mutagenesis, E2F1-/- MEF repair assays","pmids":["18348985"],"confidence":"High","gaps":["Other transcriptional inputs not surveyed","Quantitative contribution to damage-induced repair not isolated"]},{"year":2010,"claim":"Established CK2 as the dominant XRCC1 kinase required for complex stability, linking phosphorylation to ligase IIIα levels and genome integrity.","evidence":"Unbiased kinase assay, CK2-site mutagenesis, CK2 siRNA with comet assay","pmids":["20471329"],"confidence":"High","gaps":["Did not resolve which phosphosites drive which downstream events","Direct structural effect on complex not shown"]},{"year":2011,"claim":"Resolved the in vivo ligase question by showing Ligase I, not Ligase III, performs XRCC1-mediated nuclear repair, with LIG3 dedicated to mitochondrial DNA.","evidence":"Nervous-system-specific conditional XRCC1 and LIG3 knockout mice with mitochondrial DNA analysis","pmids":["21636980"],"confidence":"High","gaps":["Mechanism of ligase choice not defined","Tissue specificity of ligase usage outside nervous system not addressed"]},{"year":2014,"claim":"Reframed the Polβ and HSP90 interactions as stability/quality-control functions rather than recruitment, revealing proteostatic regulation of repair-complex architecture.","evidence":"Co-IP, ubiquitylation assays, HSP90 inhibition, siRNA, and live-cell imaging","pmids":["25423885"],"confidence":"High","gaps":["How proliferation/damage signals remodel the complex not fully defined","CHIP recognition determinants not mapped"]},{"year":2015,"claim":"Identified the BRCT1 phosphate-binding pocket as the PAR-reading module that recruits XRCC1 to damage, defining the mechanism of PARP1-dependent recruitment.","evidence":"Pocket mutagenesis, PAR binding assays, live-cell laser recruitment, PARP1 Co-IP, survival assays","pmids":["26130715"],"confidence":"High","gaps":["Structural detail of PAR-pocket binding not resolved","Relative contribution versus direct DNA binding not quantified"]},{"year":2016,"claim":"Established that XRCC1 loss causes PARP1 hyperactivation as the mechanistic driver of cerebellar neurodegeneration, providing a disease mechanism and therapeutic rationale.","evidence":"Patient fibroblasts and Xrcc1/Parp1 double-knockout mice with ADP-ribose, neuron counting, and ataxia readouts","pmids":["28002403"],"confidence":"High","gaps":["Molecular trigger of PARP1 hyperactivation not yet defined at this stage","Why cerebellum is selectively vulnerable unresolved"]},{"year":2016,"claim":"Revealed a temporally required XRCC1 repair function in terminal muscle differentiation, extending its role to developmental contexts.","evidence":"Skeletal myoblast-specific Xrcc1 deletion, live foci imaging, perinatal lethality and myofiber histology","pmids":["27462438"],"confidence":"High","gaps":["Source of caspase-triggered DNA breaks in differentiation not defined","Whether the defect is BER-specific not established"]},{"year":2017,"claim":"Showed CK2-dependent phosphorylation licenses PNKP recruitment but is dispensable for some XRCC1 repair, dissociating PNKP-dependent and -independent functions.","evidence":"Phosphorylation-mutant complementation in Xrcc1-/- fibroblasts, PNKP-GFP recruitment imaging, CPT/H2O2 survival","pmids":["29100039"],"confidence":"High","gaps":["Identity of the PNKP-independent repair route not defined","Why CPT hypersensitivity reverses with the mutant unclear"]},{"year":2018,"claim":"Mapped a PNKP/DNA-binding region and showed cancer-associated R194W and R280H variants impair PNKP stimulation and recruitment, giving functional meaning to common polymorphisms.","evidence":"Domain binding and PNKP kinase assays with XRCC1 fragments; laser recruitment imaging of variants","pmids":["30446622"],"confidence":"High","gaps":["Cancer risk consequences in patients not tested here","Structural basis of variant defects not resolved"]},{"year":2018,"claim":"Connected chromatin state to XRCC1 recruitment by showing KDM5B-mediated H3K4 demethylation facilitates XRCC1 localization to damage and contributes to cisplatin resistance.","evidence":"KDM5B manipulation, Co-IP, XRCC1/γH2AX co-localization, H3K4 methylation and pharmacological inhibition","pmids":["29989047"],"confidence":"Medium","gaps":["Link between demethylation and recruitment inferred from co-localization, not biochemically reconstituted","Direct XRCC1–chromatin contact not demonstrated"]},{"year":2019,"claim":"Defined post-translational control of XRCC1 abundance, with SIRT1 deacetylation blocking β-TrCP ubiquitination and a central DNA-binding domain governing retention versus repair rate.","evidence":"Co-IP, deacetylation-site mutagenesis, ubiquitination and half-life assays; CDB mutagenesis with in vitro binding and live-cell retention imaging","pmids":["31043584","30816207"],"confidence":"High","gaps":["How retention duration is normally set in vivo unclear","Coupling of acetylation status to repair activity not established"]},{"year":2020,"claim":"Uncovered a non-canonical XRCC1 role in alternative end-joining at stalled forks via a POLQ/MRE11 complex normally restrained by BRCA2, linking XRCC1 to replication-stress tolerance.","evidence":"In vitro alt-EJ reconstitution, Co-IP with POLQ/MRE11, BRCA2/XRCC1 co-depletion, fork restart and aberration assays","pmids":["32776008"],"confidence":"Medium","gaps":["Single-lab reconstitution in a novel pathway context","In vivo significance of XRCC1-driven alt-EJ not established"]},{"year":2021,"claim":"Defined XRCC1 as an anti-trapper that prevents PARP1 from becoming trapped on BER intermediates and showed aberrant PARP1 activity blocks transcriptional recovery via USP3, unifying the toxicity mechanism of XRCC1 loss.","evidence":"XRCC1-knockout cells, PARP1 trapping and BER accessibility assays, PARP1/USP3 deletion epistasis, histone ubiquitination and transcription recovery in neurons and patient fibroblasts","pmids":["34102106","34811483"],"confidence":"High","gaps":["Structural basis of how XRCC1 displaces/limits PARP1 unresolved","Generality of transcription-block mechanism across tissues not fully tested"]},{"year":2022,"claim":"Established a reciprocal recruitment dependency between PARP1 and XRCC1 and confirmed that PARP1 deletion partially rescues XRCC1-deficient repair and survival.","evidence":"PARP1/XRCC1 single and double KO HeLa cells, live recruitment imaging, NAD+, survival, and comet assays","pmids":["35778544"],"confidence":"High","gaps":["Mechanism of the mutual recruitment dependency not resolved","Only partial rescue indicates additional PARP1-independent defects"]},{"year":null,"claim":"The structural mechanism by which XRCC1 physically limits and displaces PARP1 on BER intermediates, and how its multiple recruitment cues (PAR, direct DNA, chromatin marks) are integrated, remain undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of an XRCC1-bound repair intermediate with PARP1","Quantitative hierarchy among PAR-, DNA-, and chromatin-based recruitment unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[5,17]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,3,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,18]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,18]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,17,14]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[1,6]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,6,11]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[10,12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8]}],"complexes":["XRCC1–DNA ligase IIIα complex","XRCC1–Polβ heterodimer","XRCC1–POLQ–MRE11 alt-EJ complex"],"partners":["LIG3","POLB","PNKP","PARP1","PCNA","POLQ","MRE11","HSP90"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P18887","full_name":"DNA repair protein XRCC1","aliases":["X-ray repair cross-complementing protein 1"],"length_aa":633,"mass_kda":69.5,"function":"Scaffold protein involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes (PubMed:11163244, PubMed:28002403). Negatively regulates ADP-ribosyltransferase activity of PARP1 during base-excision repair in order to prevent excessive PARP1 activity (PubMed:28002403, PubMed:34102106, PubMed:34811483). Recognizes and binds poly-ADP-ribose chains: specifically binds auto-poly-ADP-ribosylated PARP1, limiting its activity (PubMed:14500814, PubMed:34102106, PubMed:34811483)","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P18887/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/XRCC1","classification":"Not Classified","n_dependent_lines":301,"n_total_lines":1208,"dependency_fraction":0.24917218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HMGN5","stoichiometry":0.2},{"gene":"NUMA1","stoichiometry":0.2},{"gene":"PARP1","stoichiometry":0.2},{"gene":"PBK","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2},{"gene":"TDP1","stoichiometry":0.2},{"gene":"TOP1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/XRCC1","total_profiled":1310},"omim":[{"mim_id":"617633","title":"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 26; SCAR26","url":"https://www.omim.org/entry/617633"},{"mim_id":"615884","title":"ADIPOCYTE PLASMA MEMBRANE-ASSOCIATED PROTEIN; APMAP","url":"https://www.omim.org/entry/615884"},{"mim_id":"611035","title":"APRATAXIN- AND PNKP-LIKE FACTOR; APLF","url":"https://www.omim.org/entry/611035"},{"mim_id":"607725","title":"POLY(ADP-RIBOSE) POLYMERASE 2; PARP2","url":"https://www.omim.org/entry/607725"},{"mim_id":"607207","title":"STIP1 HOMOLOGOUS AND U BOX-CONTAINING PROTEIN 1; STUB1","url":"https://www.omim.org/entry/607207"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/XRCC1"},"hgnc":{"alias_symbol":[],"prev_symbol":["RCC"]},"alphafold":{"accession":"P18887","domains":[{"cath_id":"2.60.120.260","chopping":"4-155","consensus_level":"high","plddt":90.7143,"start":4,"end":155},{"cath_id":"3.40.50.10190","chopping":"315-402","consensus_level":"high","plddt":90.4057,"start":315,"end":402},{"cath_id":"3.40.50.10190","chopping":"548-628","consensus_level":"high","plddt":92.5044,"start":548,"end":628}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P18887","model_url":"https://alphafold.ebi.ac.uk/files/AF-P18887-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P18887-F1-predicted_aligned_error_v6.png","plddt_mean":69.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=XRCC1","jax_strain_url":"https://www.jax.org/strain/search?query=XRCC1"},"sequence":{"accession":"P18887","fasta_url":"https://rest.uniprot.org/uniprotkb/P18887.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P18887/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P18887"}},"corpus_meta":[{"pmid":"12967653","id":"PMC_12967653","title":"XRCC1 and DNA strand break repair.","date":"2003","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/12967653","citation_count":502,"is_preprint":false},{"pmid":"9136882","id":"PMC_9136882","title":"XRCC1 protein interacts with one of two distinct forms of DNA ligase III.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9136882","citation_count":227,"is_preprint":false},{"pmid":"28002403","id":"PMC_28002403","title":"XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia.","date":"2016","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28002403","citation_count":223,"is_preprint":false},{"pmid":"21952069","id":"PMC_21952069","title":"Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.","date":"2011","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/21952069","citation_count":212,"is_preprint":false},{"pmid":"20679884","id":"PMC_20679884","title":"Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.","date":"2010","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20679884","citation_count":173,"is_preprint":false},{"pmid":"15107487","id":"PMC_15107487","title":"XRCC1 co-localizes and physically interacts with PCNA.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15107487","citation_count":163,"is_preprint":false},{"pmid":"34102106","id":"PMC_34102106","title":"XRCC1 prevents toxic PARP1 trapping during DNA base excision repair.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/34102106","citation_count":161,"is_preprint":false},{"pmid":"12565173","id":"PMC_12565173","title":"Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer.","date":"2003","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12565173","citation_count":158,"is_preprint":false},{"pmid":"31324530","id":"PMC_31324530","title":"XRCC1 protein; Form and function.","date":"2019","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/31324530","citation_count":139,"is_preprint":false},{"pmid":"28644440","id":"PMC_28644440","title":"LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28644440","citation_count":137,"is_preprint":false},{"pmid":"10743659","id":"PMC_10743659","title":"Molecular cloning, functional expression and characterisation of RCC reductase involved in chlorophyll catabolism.","date":"2000","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10743659","citation_count":117,"is_preprint":false},{"pmid":"25795425","id":"PMC_25795425","title":"The structural basis of XRCC1-mediated DNA repair.","date":"2015","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/25795425","citation_count":111,"is_preprint":false},{"pmid":"16397295","id":"PMC_16397295","title":"XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA damage.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16397295","citation_count":105,"is_preprint":false},{"pmid":"26130715","id":"PMC_26130715","title":"The XRCC1 phosphate-binding pocket binds poly (ADP-ribose) and is required for XRCC1 function.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26130715","citation_count":95,"is_preprint":false},{"pmid":"25423885","id":"PMC_25423885","title":"HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase β.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25423885","citation_count":94,"is_preprint":false},{"pmid":"12359351","id":"PMC_12359351","title":"Genetic polymorphisms of XRCC1 and risk of gastric cancer.","date":"2002","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12359351","citation_count":88,"is_preprint":false},{"pmid":"34575959","id":"PMC_34575959","title":"Loss of Von Hippel-Lindau (VHL) Tumor Suppressor Gene Function: VHL-HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC).","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34575959","citation_count":81,"is_preprint":false},{"pmid":"18330515","id":"PMC_18330515","title":"XRCC1 and XRCC3 variants and risk of glioma and meningioma.","date":"2008","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18330515","citation_count":77,"is_preprint":false},{"pmid":"24351440","id":"PMC_24351440","title":"MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.","date":"2013","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24351440","citation_count":75,"is_preprint":false},{"pmid":"16621887","id":"PMC_16621887","title":"Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma.","date":"2006","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16621887","citation_count":70,"is_preprint":false},{"pmid":"17116943","id":"PMC_17116943","title":"Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.","date":"2006","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17116943","citation_count":67,"is_preprint":false},{"pmid":"16550161","id":"PMC_16550161","title":"Mouse models of XRCC1 DNA repair polymorphisms and cancer.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16550161","citation_count":62,"is_preprint":false},{"pmid":"17898525","id":"PMC_17898525","title":"DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas.","date":"2007","source":"Neuroepidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/17898525","citation_count":60,"is_preprint":false},{"pmid":"34811483","id":"PMC_34811483","title":"XRCC1 protects transcription from toxic PARP1 activity during DNA base excision repair.","date":"2021","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34811483","citation_count":57,"is_preprint":false},{"pmid":"36445063","id":"PMC_36445063","title":"STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36445063","citation_count":55,"is_preprint":false},{"pmid":"29989047","id":"PMC_29989047","title":"KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.","date":"2018","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29989047","citation_count":55,"is_preprint":false},{"pmid":"24053727","id":"PMC_24053727","title":"Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).","date":"2014","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/24053727","citation_count":54,"is_preprint":false},{"pmid":"23225521","id":"PMC_23225521","title":"Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23225521","citation_count":53,"is_preprint":false},{"pmid":"15533591","id":"PMC_15533591","title":"Polymorphisms of XRCC1 and risk of esophageal and gastric cardia cancer.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15533591","citation_count":53,"is_preprint":false},{"pmid":"15610045","id":"PMC_15610045","title":"Biophysical characterization of human XRCC1 and its binding to damaged and undamaged DNA.","date":"2004","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15610045","citation_count":53,"is_preprint":false},{"pmid":"15800946","id":"PMC_15800946","title":"Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15800946","citation_count":52,"is_preprint":false},{"pmid":"20471329","id":"PMC_20471329","title":"XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair.","date":"2010","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/20471329","citation_count":52,"is_preprint":false},{"pmid":"31043584","id":"PMC_31043584","title":"SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31043584","citation_count":51,"is_preprint":false},{"pmid":"21604176","id":"PMC_21604176","title":"Polymorphisms of XRCC1 and gastric cancer susceptibility: a meta-analysis.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21604176","citation_count":50,"is_preprint":false},{"pmid":"17264068","id":"PMC_17264068","title":"XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17264068","citation_count":50,"is_preprint":false},{"pmid":"16492913","id":"PMC_16492913","title":"Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma.","date":"2006","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16492913","citation_count":50,"is_preprint":false},{"pmid":"33510354","id":"PMC_33510354","title":"Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33510354","citation_count":49,"is_preprint":false},{"pmid":"32776008","id":"PMC_32776008","title":"XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells.","date":"2020","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32776008","citation_count":47,"is_preprint":false},{"pmid":"26526752","id":"PMC_26526752","title":"A river model to map convergent cancer evolution and guide therapy in RCC.","date":"2015","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/26526752","citation_count":46,"is_preprint":false},{"pmid":"33087283","id":"PMC_33087283","title":"XRCC1 - Strategies for coordinating and assembling a versatile DNA damage response.","date":"2020","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/33087283","citation_count":45,"is_preprint":false},{"pmid":"22249190","id":"PMC_22249190","title":"Epigenetic regulation in RCC: opportunities for therapeutic intervention?","date":"2012","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/22249190","citation_count":42,"is_preprint":false},{"pmid":"17721277","id":"PMC_17721277","title":"Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications.","date":"2007","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/17721277","citation_count":42,"is_preprint":false},{"pmid":"14639127","id":"PMC_14639127","title":"CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx.","date":"2003","source":"European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)","url":"https://pubmed.ncbi.nlm.nih.gov/14639127","citation_count":42,"is_preprint":false},{"pmid":"22041025","id":"PMC_22041025","title":"XRCC1 and base excision repair balance in response to nitric oxide.","date":"2011","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/22041025","citation_count":42,"is_preprint":false},{"pmid":"20399960","id":"PMC_20399960","title":"Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC).","date":"2010","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20399960","citation_count":41,"is_preprint":false},{"pmid":"17650498","id":"PMC_17650498","title":"XRCC1 stimulates polynucleotide kinase by enhancing its damage discrimination and displacement from DNA repair intermediates.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17650498","citation_count":40,"is_preprint":false},{"pmid":"17935911","id":"PMC_17935911","title":"Menopausal age and XRCC1 gene polymorphisms: role in breast cancer risk.","date":"2007","source":"Cancer detection and prevention","url":"https://pubmed.ncbi.nlm.nih.gov/17935911","citation_count":39,"is_preprint":false},{"pmid":"1353960","id":"PMC_1353960","title":"Alterations in expression and structure of the DNA repair gene XRCC1.","date":"1992","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1353960","citation_count":39,"is_preprint":false},{"pmid":"22025172","id":"PMC_22025172","title":"The complex roles of Wnt antagonists in RCC.","date":"2011","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/22025172","citation_count":38,"is_preprint":false},{"pmid":"19673050","id":"PMC_19673050","title":"Polymorphisms of XRCC1 gene and risk of gastric cardiac adenocarcinoma.","date":"2009","source":"Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus","url":"https://pubmed.ncbi.nlm.nih.gov/19673050","citation_count":38,"is_preprint":false},{"pmid":"18999926","id":"PMC_18999926","title":"XRCC1 polymorphism and lung cancer risk.","date":"2008","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/18999926","citation_count":37,"is_preprint":false},{"pmid":"23226053","id":"PMC_23226053","title":"ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.","date":"2011","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23226053","citation_count":37,"is_preprint":false},{"pmid":"19528960","id":"PMC_19528960","title":"Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.","date":"2009","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/19528960","citation_count":36,"is_preprint":false},{"pmid":"17425776","id":"PMC_17425776","title":"DNA repair gene XRCC1 polymorphisms and bladder cancer risk.","date":"2007","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17425776","citation_count":36,"is_preprint":false},{"pmid":"26231735","id":"PMC_26231735","title":"Infiltrating neutrophils promote renal cell carcinoma (RCC) proliferation via modulating androgen receptor (AR) → c-Myc signals.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26231735","citation_count":36,"is_preprint":false},{"pmid":"31201813","id":"PMC_31201813","title":"SIRT1 downregulated FGB expression to inhibit RCC tumorigenesis by destabilizing STAT3.","date":"2019","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31201813","citation_count":35,"is_preprint":false},{"pmid":"31602010","id":"PMC_31602010","title":"Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities.","date":"2019","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/31602010","citation_count":32,"is_preprint":false},{"pmid":"33949971","id":"PMC_33949971","title":"Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33949971","citation_count":31,"is_preprint":false},{"pmid":"26815503","id":"PMC_26815503","title":"SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26815503","citation_count":31,"is_preprint":false},{"pmid":"23736025","id":"PMC_23736025","title":"Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23736025","citation_count":30,"is_preprint":false},{"pmid":"31669203","id":"PMC_31669203","title":"PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31669203","citation_count":30,"is_preprint":false},{"pmid":"16245950","id":"PMC_16245950","title":"DNA damage levels and biochemical repair capacities associated with XRCC1 deficiency.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16245950","citation_count":29,"is_preprint":false},{"pmid":"8524362","id":"PMC_8524362","title":"Expression of the DNA repair gene XRCC1 in baboon tissues.","date":"1995","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/8524362","citation_count":28,"is_preprint":false},{"pmid":"33535553","id":"PMC_33535553","title":"Identification of RCC Subtype-Specific microRNAs-Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33535553","citation_count":27,"is_preprint":false},{"pmid":"37173306","id":"PMC_37173306","title":"PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37173306","citation_count":26,"is_preprint":false},{"pmid":"27793664","id":"PMC_27793664","title":"Rock2 promotes RCC proliferation by decreasing SCARA5 expression through β-catenin/TCF4 signaling.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27793664","citation_count":25,"is_preprint":false},{"pmid":"27462438","id":"PMC_27462438","title":"Temporal activation of XRCC1-mediated DNA repair is essential for muscle differentiation.","date":"2016","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27462438","citation_count":25,"is_preprint":false},{"pmid":"22843073","id":"PMC_22843073","title":"MLH1 and XRCC1 polymorphisms in Mexican patients with colorectal cancer.","date":"2012","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/22843073","citation_count":24,"is_preprint":false},{"pmid":"40680722","id":"PMC_40680722","title":"YTHDC1 lactylation regulates its phase separation to enhance target mRNA stability and promote RCC progression.","date":"2025","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/40680722","citation_count":22,"is_preprint":false},{"pmid":"18247046","id":"PMC_18247046","title":"Characterization of plant XRCC1 and its interaction with proliferating cell nuclear antigen.","date":"2008","source":"Planta","url":"https://pubmed.ncbi.nlm.nih.gov/18247046","citation_count":22,"is_preprint":false},{"pmid":"33502949","id":"PMC_33502949","title":"Suppression of lncRNA HOTAIR alleviates RCC angiogenesis through regulating miR-126/EGFL7 axis.","date":"2021","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33502949","citation_count":22,"is_preprint":false},{"pmid":"33729862","id":"PMC_33729862","title":"ALK-rearranged Renal Cell Carcinoma (RCC): A Report of 2 Cases and Review of the Literature Emphasizing the Distinction Between VCL-ALK and Non-VCL-ALK RCC.","date":"2021","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33729862","citation_count":22,"is_preprint":false},{"pmid":"21636980","id":"PMC_21636980","title":"Disconnecting XRCC1 and DNA ligase III.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21636980","citation_count":21,"is_preprint":false},{"pmid":"28107702","id":"PMC_28107702","title":"C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion.","date":"2017","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28107702","citation_count":21,"is_preprint":false},{"pmid":"18348985","id":"PMC_18348985","title":"E2F1 regulates the base excision repair gene XRCC1 and promotes DNA repair.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18348985","citation_count":21,"is_preprint":false},{"pmid":"29520425","id":"PMC_29520425","title":"Differentiating papillary type I RCC from clear cell RCC and oncocytoma: application of whole-lesion volumetric ADC measurement.","date":"2018","source":"Abdominal radiology (New York)","url":"https://pubmed.ncbi.nlm.nih.gov/29520425","citation_count":21,"is_preprint":false},{"pmid":"30328556","id":"PMC_30328556","title":"Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma.","date":"2018","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/30328556","citation_count":20,"is_preprint":false},{"pmid":"18474019","id":"PMC_18474019","title":"New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects.","date":"2008","source":"Reviews on recent clinical trials","url":"https://pubmed.ncbi.nlm.nih.gov/18474019","citation_count":20,"is_preprint":false},{"pmid":"32207384","id":"PMC_32207384","title":"Circular RNA circMTO1 Suppresses RCC Cancer Cell Progression via miR9/LMX1A Axis.","date":"2020","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/32207384","citation_count":19,"is_preprint":false},{"pmid":"29051029","id":"PMC_29051029","title":"Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies.","date":"2017","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29051029","citation_count":19,"is_preprint":false},{"pmid":"24906341","id":"PMC_24906341","title":"Association between DNA repair genes (XPD and XRCC1) polymorphisms and susceptibility to age-related cataract (ARC): a meta-analysis.","date":"2014","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/24906341","citation_count":18,"is_preprint":false},{"pmid":"26271249","id":"PMC_26271249","title":"Genetic polymorphisms in XRCC1 genes and colorectal cancer susceptibility.","date":"2015","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26271249","citation_count":18,"is_preprint":false},{"pmid":"28991497","id":"PMC_28991497","title":"Polymorphisms of DNA repair genes XRCC1 and LIG4 and idiopathic male infertility.","date":"2017","source":"Systems biology in reproductive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28991497","citation_count":18,"is_preprint":false},{"pmid":"30362960","id":"PMC_30362960","title":"XRCC1 gene polymorphisms and risk of neuroblastoma in Chinese children.","date":"2018","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/30362960","citation_count":17,"is_preprint":false},{"pmid":"30816207","id":"PMC_30816207","title":"Identification of an XRCC1 DNA binding activity essential for retention at sites of DNA damage.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30816207","citation_count":17,"is_preprint":false},{"pmid":"34090649","id":"PMC_34090649","title":"Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC.","date":"2021","source":"Seminars in radiation oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34090649","citation_count":17,"is_preprint":false},{"pmid":"30446622","id":"PMC_30446622","title":"Domain analysis of PNKP-XRCC1 interactions: Influence of genetic variants of XRCC1.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30446622","citation_count":17,"is_preprint":false},{"pmid":"28315507","id":"PMC_28315507","title":"Polymorphisms and mutations in GSTP1, RAD51, XRCC1 and XRCC3 genes in breast cancer patients.","date":"2017","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/28315507","citation_count":16,"is_preprint":false},{"pmid":"32426369","id":"PMC_32426369","title":"XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer.","date":"2020","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/32426369","citation_count":16,"is_preprint":false},{"pmid":"36510217","id":"PMC_36510217","title":"Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/36510217","citation_count":16,"is_preprint":false},{"pmid":"38218876","id":"PMC_38218876","title":"Predictive value of SIRI and SII for metastases in RCC: a prospective clinical study.","date":"2024","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/38218876","citation_count":15,"is_preprint":false},{"pmid":"20577654","id":"PMC_20577654","title":"XRCC1, but not APE1 and hOGG1 gene polymorphisms is a risk factor for pterygium.","date":"2010","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/20577654","citation_count":15,"is_preprint":false},{"pmid":"35778544","id":"PMC_35778544","title":"PARP1 and XRCC1 exhibit a reciprocal relationship in genotoxic stress response.","date":"2022","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35778544","citation_count":14,"is_preprint":false},{"pmid":"29552790","id":"PMC_29552790","title":"Haplotype analysis of XRCC1 gene polymorphisms and the risk of thyroid carcinoma.","date":"2018","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29552790","citation_count":14,"is_preprint":false},{"pmid":"36553076","id":"PMC_36553076","title":"Potential Value of Visfatin, Omentin-1, Nesfatin-1 and Apelin in Renal Cell Carcinoma (RCC): A Systematic Review and Meta-Analysis.","date":"2022","source":"Diagnostics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36553076","citation_count":14,"is_preprint":false},{"pmid":"25638704","id":"PMC_25638704","title":"Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.","date":"2015","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25638704","citation_count":14,"is_preprint":false},{"pmid":"36823017","id":"PMC_36823017","title":"The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis.","date":"2023","source":"Clinical genitourinary cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36823017","citation_count":14,"is_preprint":false},{"pmid":"29100039","id":"PMC_29100039","title":"XRCC1-mediated repair of strand breaks independent of PNKP binding.","date":"2017","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/29100039","citation_count":14,"is_preprint":false},{"pmid":"32569823","id":"PMC_32569823","title":"The influence of dysbiosis on kidney stones that risk up renal cell carcinoma (RCC).","date":"2020","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/32569823","citation_count":14,"is_preprint":false},{"pmid":"25245010","id":"PMC_25245010","title":"Association between XRCC1 polymorphisms and glioma risk among Chinese population.","date":"2014","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25245010","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50575,"output_tokens":6705,"usd":0.12615,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15628,"output_tokens":5964,"usd":0.11362,"stage2_stop_reason":"end_turn"},"total_usd":0.23977,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"The C-terminal 96 amino acids of XRCC1 are necessary and sufficient for direct interaction with DNA ligase III (103 kDa form), and the C-terminal 148 amino acids of DNA ligase III contain the binding site for XRCC1. The alternatively spliced 96 kDa testis form of DNA ligase III lacks this interaction, indicating only the 103 kDa isoform partners with XRCC1 in base excision repair.\",\n      \"method\": \"Far Western analysis and affinity precipitation with subcloned XRCC1 and DNA ligase III fragments; antipeptide antibodies to distinguish isoforms\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro domain-mapping reconstitution with multiple truncation fragments and orthogonal methods (far Western + affinity precipitation + antibody discrimination of isoforms)\",\n      \"pmids\": [\"9136882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"XRCC1 co-localizes with PCNA at DNA replication foci exclusively in S phase of undamaged HeLa cells, physically interacts with PCNA in vivo (shown by FRET and co-immunoprecipitation), and the interaction is mediated by XRCC1 residues 166–310 in vitro, suggesting XRCC1 is sequestered to replication factories via PCNA to facilitate single-strand break repair in S phase.\",\n      \"method\": \"Fluorescence co-localization, FRET analysis, co-immunoprecipitation, in vitro biochemical assay with XRCC1 truncation fragments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus FRET plus in vitro domain mapping, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15107487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"XRCC1 is phosphorylated at serine 371 by the DNA-PK complex (interacting via the BRCT1 domain) in response to ionizing radiation. This phosphorylation causes XRCC1 dimer dissociation. The non-phosphorylable S371L mutant fails to fully rescue DSB repair defects in XRCC1-deficient EM9 cells, establishing a functional role for DNA-PK-mediated XRCC1 phosphorylation in DSB repair. XRCC1 also strongly stimulates DNA-PK-mediated phosphorylation of p53-Ser15.\",\n      \"method\": \"GST-BRCT1 pulldown followed by mass spectrometry; phosphorylation assays; XRCC1 mutant (S371D and S371L) rescue of EM9 cells; in vitro kinase assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assay with mutagenesis, pulldown-MS identification of kinase, functional rescue experiment, multiple orthogonal methods in one study\",\n      \"pmids\": [\"16397295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"XRCC1 stimulates polynucleotide kinase (PNK) activity by two mechanisms: (1) enhancing PNK's ability to discriminate between 5'-OH and 5'-phosphate termini at strand breaks, and (2) displacing PNK from the phosphorylated DNA product, thereby accelerating PNK turnover.\",\n      \"method\": \"Fluorescence binding assays, fluorescence anisotropy, kinetic assays at limiting enzyme concentration with XRCC1 and PNK on defined DNA substrates\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro system with defined DNA substrates, multiple fluorescence methods, mechanistic discrimination of two activities, single lab\",\n      \"pmids\": [\"17650498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Casein kinase 2 (CK2) is the major kinase responsible for XRCC1 phosphorylation in human cell extracts. CK2-mediated phosphorylation is required for stability of the XRCC1–DNA ligase IIIα complex; mutation of CK2 phosphorylation sites in XRCC1 destabilizes this complex. siRNA knockdown of CK2 reduces XRCC1 phosphorylation and stability, decreases Lig III levels, and leads to accumulation of DNA strand breaks.\",\n      \"method\": \"Unbiased kinase activity assay in cell extracts; site-directed mutagenesis of CK2 phosphorylation sites; siRNA knockdown of CK2; comet assay for strand breaks\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — unbiased biochemical identification of kinase, mutagenesis validation, siRNA knockdown with functional readout, multiple orthogonal methods\",\n      \"pmids\": [\"20471329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Purified full-length human XRCC1 exists as a monomer at low concentrations and forms a dimer at higher concentrations (Kd ~570 nM). It preferentially binds DNA containing single-strand breaks with gaps ≤1 nucleotide (Kd 34–65 nM) compared to 5-nucleotide gaps, intact duplex, or single-stranded DNA (Kd ~215–260 nM), indicating selective recognition of short-gap SSBs.\",\n      \"method\": \"Sedimentation equilibrium ultracentrifugation, fluorescence titration binding assays with defined model DNA substrates\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — purified recombinant protein, biophysical reconstitution with multiple defined substrates, quantitative binding constants determined\",\n      \"pmids\": [\"15610045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The phosphate-binding pocket within XRCC1's central BRCT1 domain is required for selective binding to poly(ADP-ribose) (PAR) at low ADP-ribosylation levels and promotes interaction with cellular PARP1. This pocket is required for XRCC1 recruitment to UVA laser, H2O2 damage sites, and sub-nuclear PCNA foci, and is essential for XRCC1-dependent acceleration of SSBR, BER, and cell survival after DNA damage.\",\n      \"method\": \"Mutagenesis of phosphate-binding pocket residues; PAR binding assays; EGFP-XRCC1 live-cell recruitment at laser-induced damage; co-immunoprecipitation with PARP1; clonogenic survival and repair kinetics assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis combined with live-cell imaging, Co-IP, and functional survival assays, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"26130715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The XRCC1–DNA polymerase β heterodimer is not required for DNA damage response or recruitment to damage sites; instead, heterodimer formation protects Polβ from CHIP-mediated ubiquitylation and degradation. XRCC1 monomer stability is independently protected from CHIP by binding to HSP90. In response to cellular proliferation and DNA damage, HSP90- and proteasome-mediated regulation alters the repair complex architecture.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitylation assays; HSP90 inhibitor (17-AAG) treatment; siRNA knockdown; live-cell imaging of DNA damage response\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitylation assay, pharmacological inhibition, and knockdown with functional readout; multiple orthogonal methods in one study\",\n      \"pmids\": [\"25423885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Biallelic XRCC1 mutations in patients cause elevated PARP1 hyperactivation (elevated protein ADP-ribosylation) and single-strand break repair deficiency. Genetic deletion of Parp1 in Xrcc1-deficient mice rescues normal cerebellar ADP-ribose levels, reduces cerebellar neuron loss, and reduces ataxia, establishing that PARP1 hyperactivation caused by loss of XRCC1 is the mechanistic driver of cerebellar neuropathology.\",\n      \"method\": \"Patient-derived fibroblast analysis; Xrcc1/Parp1 double-knockout mouse model; ADP-ribosylation quantification; cerebellar neuron counting; behavioral ataxia scoring\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in mouse KO model plus patient cell analysis, replicated across multiple experimental systems\",\n      \"pmids\": [\"28002403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"XRCC1 assembles complexes containing DNA polymerase β and DNA ligase III that prevent excessive PARP1 engagement and activity during BER. In XRCC1-deficient cells, PARP1 becomes 'trapped' on BER intermediates (similar to PARP inhibitor trapping), blocking access of repair enzymes such as Polβ. Deletion of PARP1 rescues BER and resistance to base damage in XRCC1-knockout cells.\",\n      \"method\": \"XRCC1-knockout cell lines; PARP1 trapping assays; BER intermediate accessibility assays; PARP1 deletion epistasis; patient fibroblast validation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO epistasis, PARP trapping assays, patient cell validation, multiple orthogonal methods replicated across cell types\",\n      \"pmids\": [\"34102106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"XRCC1 loss causes failure to recover transcription after DNA base damage due to aberrant/excessive PARP1 activity during BER. This aberrant PARP1 activity promotes excessive recruitment of the ubiquitin protease USP3, which reduces monoubiquitinated histones required for normal transcriptional regulation. Inhibition or deletion of PARP1 or USP3 restores transcriptional recovery in XRCC1-deficient cells.\",\n      \"method\": \"XRCC1-knockout human cells and Xrcc1-/- mouse neurons; transcription recovery assays; USP3 inhibition/deletion; histone ubiquitination measurement; PARP1 inhibition rescue\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with mechanistic pathway dissection through multiple orthogonal interventions (PARP1 inhibition, USP3 deletion, histone ubiquitination measurement), validated in neurons and patient fibroblasts\",\n      \"pmids\": [\"34811483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"XRCC1-deficient cell extracts have normal base excision activity for 8-oxoguanine, 5-hydroxycytosine, ethenoadenine, and uracil; normal abasic site incision; and normal gap-filling. However, a ~2–4-fold reduction in nick ligation activity is observed, indicating that the primary biochemical defect of XRCC1 deficiency is at the ligation step of BER/SSBR.\",\n      \"method\": \"Whole-cell extract BER assays; DNA damage measurement (8-OH-dG levels); nick ligation assays with defined substrates in XRCC1-deficient (EM9) versus wild-type CHO extracts\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic in vitro reconstitution assays covering each BER step with defined substrates; multiple lesion types tested; single lab\",\n      \"pmids\": [\"16245950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"E2F1 transcription factor directly activates XRCC1 promoter transcription via E2F1 binding sites in the promoter. Ectopic wild-type E2F1 (but not a DNA-binding mutant) increases endogenous XRCC1 expression. DNA damage stimulates XRCC1 expression in E2F1+/+ but not E2F1-/- MEFs, and E2F1-/- MEFs show attenuated DNA repair after MMS treatment.\",\n      \"method\": \"Luciferase reporter assays with XRCC1 promoter deletions; conditional E2F1 expression; E2F1-/- MEF analysis; promoter E2F1 binding site deletion mutagenesis; MMS survival and repair assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter mutagenesis, genetic KO MEF rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"18348985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Genetic inactivation of LIG3 (DNA Ligase III) specifically in the nervous system reveals that LIG3 function is central to mitochondrial DNA maintenance rather than nuclear SSBR, in contrast to XRCC1. The data indicate that DNA Ligase 1 (not LIG3) is the main DNA ligase for XRCC1-mediated nuclear DNA repair.\",\n      \"method\": \"Conditional tissue-specific knockout mouse models for XRCC1 and LIG3 in developing nervous system; phenotypic comparison; mitochondrial DNA integrity analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via conditional KO mouse models with defined phenotypic readouts, comparison of XRCC1 and LIG3 knockouts\",\n      \"pmids\": [\"21636980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"XRCC1 is an indispensable mediator of muscle differentiation. Caspase-triggered XRCC1 repair foci form rapidly within differentiating myonuclei and then dissipate. Skeletal myoblast-specific deletion of Xrcc1 does not affect cell growth but causes perinatal lethality with sustained DNA damage and impaired myofiber development, demonstrating a temporally required DNA repair function for terminal differentiation.\",\n      \"method\": \"Conditional Xrcc1 deletion in skeletal myoblasts; live-cell XRCC1 repair foci imaging; perinatal lethality and myofiber histology; DNA damage markers\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific developmental phenotype, live imaging of repair foci, functional rescue experiments implied by distinct phenotypic characterization\",\n      \"pmids\": [\"27462438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SIRT1 binds and deacetylates XRCC1 at lysine residues K260, K298, and K431, preventing β-TrCP E3 ligase-mediated poly-ubiquitination and proteasomal degradation of XRCC1. Mutations of these three lysine sites abrogate interaction with β-TrCP and prolong XRCC1 protein half-life, conferring chemoresistance.\",\n      \"method\": \"Co-immunoprecipitation; SIRT1 knockdown/inhibition; ubiquitination assays; site-directed mutagenesis of XRCC1 lysine residues; cycloheximide chase for protein half-life\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct deacetylation site identified by mutagenesis, ubiquitination assays, Co-IP, and half-life measurements; multiple orthogonal methods\",\n      \"pmids\": [\"31043584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"KDM5B demethylase demethylates H3K4 at DNA damage sites and facilitates recruitment of XRCC1 to γH2AX-marked damage. KDM5B knockdown increases H3K4 methylation and blocks XRCC1 localization to DNA damage sites. HSP90 protects KDM5B from ubiquitin-dependent proteasomal degradation, and the HSP90–KDM5B–XRCC1 axis mediates cisplatin resistance.\",\n      \"method\": \"KDM5B knockdown/overexpression; co-immunoprecipitation (HSP90–KDM5B); co-localization of XRCC1 with γH2AX; H3K4 methylation analysis; JIB-04 and 17-AAG pharmacological inhibition; mass spectrometry\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and co-localization with KDM5B manipulation, but the direct mechanistic link between H3K4 demethylation and XRCC1 recruitment is inferred from co-localization rather than direct biochemical reconstitution\",\n      \"pmids\": [\"29989047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"XRCC1 contains a central DNA binding domain (CDB, residues 219–415) encompassing the BRCT1 domain. Unlike the N-terminal domain, the CDB binds DNA without specificity for nicked or gapped substrates. Alanine substitutions in the CDB disrupt DNA binding in vitro and reduce XRCC1 retention (but not initial recruitment) at DNA damage sites, and reduced retention is associated with an increased rate of repair.\",\n      \"method\": \"XRCC1 domain truncation/mutagenesis; in vitro DNA binding assays; laser microirradiation with live-cell fluorescence imaging of XRCC1 accumulation kinetics\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro mutagenesis combined with live-cell imaging of recruitment and retention, domain-specific functional dissection\",\n      \"pmids\": [\"30816207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"XRCC1 residues 166–436 bind tightly to PNKP and DNA and efficiently activate PNKP's kinase activity. Cancer-associated SNP variants R194W and R280H in this fragment show considerably weaker PNKP interaction and severely reduced stimulation of PNKP kinase activity. In cells, these XRCC1 variants show reduced ability to recruit PNKP to laser-microirradiation-induced DNA damage sites.\",\n      \"method\": \"Domain binding assays; PNKP kinase activity assays with XRCC1 fragments; laser microirradiation with fluorescence microscopy of PNKP recruitment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assay with domain mapping plus live-cell PNKP recruitment imaging; SNP variant functional characterization\",\n      \"pmids\": [\"30446622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CK2-mediated phosphorylation of XRCC1 at multiple consensus sites is required for PNKP binding to XRCC1 and efficient PNKP recruitment to DNA damage. A phosphorylation mutant XRCC1 that eliminates PNKP binding fails to support efficient PNKP recruitment to microirradiation-induced damage. However, cells expressing this PNKP interaction mutant of XRCC1 show marked reversal of CPT hypersensitivity, revealing XRCC1-dependent repair that does not require phosphorylation-dependent PNKP recruitment.\",\n      \"method\": \"Stable expression of XRCC1 phosphorylation mutant in Xrcc1-/- mouse fibroblasts; PNKP-GFP microirradiation recruitment assay; clonogenic survival after CPT and H2O2\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic complementation in Xrcc1-/- cells with phosphorylation mutant, live-cell fluorescence imaging, survival assays; multiple orthogonal methods\",\n      \"pmids\": [\"29100039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"After replication stress, XRCC1 forms an active repair complex with POLQ and MRE11 that supports alternative end-joining (alt-EJ/MMEJ) activity in vitro. BRCA2 normally limits XRCC1 recruitment and complex formation to suppress alt-EJ at stalled forks. In BRCA2-deficient cells, XRCC1 enables replication completion via MRE11-dependent fork resection and restart at the expense of increased genome instability.\",\n      \"method\": \"In vitro alt-EJ reconstitution assay with XRCC1, POLQ, MRE11; Co-IP of XRCC1 with POLQ and MRE11; BRCA2 depletion in combination with XRCC1 depletion; replication fork restart and chromosome aberration assays\",\n      \"journal\": \"NAR cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution of complex plus Co-IP and genetic epistasis, single lab, novel pathway context\",\n      \"pmids\": [\"32776008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PARP1 and XRCC1 exhibit a reciprocal relationship: recruitment of either protein to DNA damage sites is impeded in the absence of the other in HeLa cells. In XRCC1 KO cells, hypersensitivity to CPT and impaired DNA repair can be partially rescued by additional deletion of PARP1, confirming that aberrant PARP1 activity drives toxicity in XRCC1-deficient cells.\",\n      \"method\": \"PARP1 KO, XRCC1 KO, and double KO HeLa cells; live-cell imaging of damage recruitment; NAD+ measurements; clonogenic survival; cell cycle and cell death analysis; comet assay\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic KO combinations with diverse functional readouts; reciprocal recruitment established by live imaging; single lab\",\n      \"pmids\": [\"35778544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"XRCC1 mRNA levels are substantially higher in testis (7–8 fold), ovary (3–4 fold), and brain (4–5 fold) compared to intestine, liver, and spleen, and high XRCC1 protein levels are detected in testis, suggesting a specialized role in DNA processing during meiogenesis and recombination.\",\n      \"method\": \"Northern blot analysis; tissue-specific mRNA quantification; Western blot for XRCC1 protein in rat tissues\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — tissue-specific expression pattern established by Northern blot and protein detection, replicated in baboon model (PMID 8524362); functional inference from expression pattern\",\n      \"pmids\": [\"1353960\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"XRCC1 functions as a molecular scaffold protein that coordinates DNA single-strand break repair (SSBR) and base excision repair (BER) by recruiting and stimulating multiple enzymatic activities—including polynucleotide kinase (PNK), DNA polymerase β, and DNA ligase IIIα/Ligase I—at break sites, where it is recruited via its BRCT1 domain binding to PARP1-synthesized poly(ADP-ribose) and is regulated by CK2-mediated phosphorylation (required for PNKP recruitment) and DNA-PK-mediated phosphorylation at S371 (required for DSB repair); critically, XRCC1 also acts as an 'anti-trapper' that limits excessive PARP1 engagement on BER intermediates, and loss of XRCC1 leads to toxic PARP1 hyperactivation that suppresses transcription (via USP3/histone ubiquitination) and drives cerebellar neurodegeneration reversible by PARP1 deletion.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"XRCC1 is a non-enzymatic scaffold protein that coordinates DNA single-strand break repair (SSBR) and base excision repair (BER) by physically organizing and stimulating the enzymatic machinery at break sites [#0, #11]. It selectively recognizes short-gap single-strand breaks through dedicated DNA-binding activity, with an N-terminal preference for gaps \\u22641 nucleotide and a central BRCT1-containing DNA-binding domain (residues 219\\u2013415) that mediates retention rather than initial recruitment [#5, #17]. XRCC1 is recruited to damage via its BRCT1 phosphate-binding pocket, which binds PARP1-synthesized poly(ADP-ribose) and is required for accumulation at laser-, H2O2-, and replication-associated damage [#6]. Once positioned, XRCC1 directly partners with the 103 kDa form of DNA ligase III\\u03b1, DNA polymerase \\u03b2, and polynucleotide kinase phosphatase (PNKP), stimulating PNKP catalysis by enhancing terminus discrimination and accelerating enzyme turnover [#0, #3, #18]; the principal biochemical consequence of XRCC1 loss is a defect at the ligation step of BER/SSBR [#11]. Complex architecture and stability are tuned post-translationally: CK2 phosphorylation maintains the XRCC1\\u2013ligase III\\u03b1 complex and licenses PNKP recruitment, DNA-PK phosphorylation at S371 dissociates XRCC1 dimers and supports DSB repair, and heterodimer formation plus HSP90 binding protect XRCC1 and Pol\\u03b2 from CHIP-mediated degradation [#2, #4, #7, #19]. Beyond catalyzing repair, XRCC1 acts as an anti-trapper that restrains excessive PARP1 engagement on BER intermediates; in its absence PARP1 becomes trapped and hyperactivated, blocking repair-enzyme access, suppressing transcriptional recovery through USP3-driven loss of histone monoubiquitination, and driving cerebellar neurodegeneration that is rescued by PARP1 deletion [#9, #10, #8, #21]. Biallelic XRCC1 mutations cause a human SSBR-deficiency syndrome with PARP1 hyperactivation and cerebellar ataxia [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established that XRCC1 is expressed at elevated levels in specific tissues, raising the question of where its repair function is most critical.\",\n      \"evidence\": \"Northern and Western analysis across rat tissues\",\n      \"pmids\": [\"1353960\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Expression pattern alone does not define molecular function\", \"Functional role in meiosis/recombination inferred, not tested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified the first direct partner of XRCC1, defining it as a scaffold that recruits a ligase rather than acting catalytically itself.\",\n      \"evidence\": \"Far Western and affinity precipitation with XRCC1 and DNA ligase III truncation fragments, isoform-specific antibodies\",\n      \"pmids\": [\"9136882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish which ligase performs nuclear repair in vivo\", \"Functional consequence of the interaction not measured\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed XRCC1 selectively recognizes short-gap single-strand breaks and is recruited to replication factories via PCNA, linking scaffold function to substrate specificity and S-phase repair.\",\n      \"evidence\": \"Sedimentation equilibrium and fluorescence titration with defined DNA substrates; FRET, Co-IP, and in vitro domain mapping in HeLa cells\",\n      \"pmids\": [\"15610045\", \"15107487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of gap-length discrimination not resolved\", \"Physiological contribution of the PCNA interaction to repair not quantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined DNA-PK phosphorylation of XRCC1 at S371 as a regulatory switch controlling dimer state and DSB repair, extending XRCC1 function beyond SSBR.\",\n      \"evidence\": \"BRCT1 pulldown-MS, in vitro kinase assays, S371 mutant rescue of EM9 cells\",\n      \"pmids\": [\"16397295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between dimer dissociation and DSB repair unresolved\", \"Direct DSB substrate engagement not shown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated XRCC1 mechanistically stimulates PNK by enhancing terminus discrimination and accelerating turnover, showing scaffold activity directly tunes enzyme kinetics.\",\n      \"evidence\": \"Reconstituted fluorescence binding, anisotropy, and kinetic assays with PNK on defined substrates\",\n      \"pmids\": [\"17650498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain of XRCC1 mediating stimulation not mapped here\", \"In vivo relevance of turnover acceleration not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Pinpointed the ligation step as the primary biochemical defect in XRCC1 deficiency, narrowing its essential function within the BER pathway.\",\n      \"evidence\": \"Stepwise BER reconstitution assays in EM9 versus wild-type CHO extracts\",\n      \"pmids\": [\"16245950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the responsible ligase in vivo\", \"Whole-extract assay may mask redundant activities\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified E2F1 as a direct transcriptional activator of XRCC1, connecting repair capacity to cell-cycle and damage-responsive gene regulation.\",\n      \"evidence\": \"Promoter luciferase reporters, E2F1 binding-site mutagenesis, E2F1-/- MEF repair assays\",\n      \"pmids\": [\"18348985\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other transcriptional inputs not surveyed\", \"Quantitative contribution to damage-induced repair not isolated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established CK2 as the dominant XRCC1 kinase required for complex stability, linking phosphorylation to ligase III\\u03b1 levels and genome integrity.\",\n      \"evidence\": \"Unbiased kinase assay, CK2-site mutagenesis, CK2 siRNA with comet assay\",\n      \"pmids\": [\"20471329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which phosphosites drive which downstream events\", \"Direct structural effect on complex not shown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved the in vivo ligase question by showing Ligase I, not Ligase III, performs XRCC1-mediated nuclear repair, with LIG3 dedicated to mitochondrial DNA.\",\n      \"evidence\": \"Nervous-system-specific conditional XRCC1 and LIG3 knockout mice with mitochondrial DNA analysis\",\n      \"pmids\": [\"21636980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ligase choice not defined\", \"Tissue specificity of ligase usage outside nervous system not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Reframed the Pol\\u03b2 and HSP90 interactions as stability/quality-control functions rather than recruitment, revealing proteostatic regulation of repair-complex architecture.\",\n      \"evidence\": \"Co-IP, ubiquitylation assays, HSP90 inhibition, siRNA, and live-cell imaging\",\n      \"pmids\": [\"25423885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How proliferation/damage signals remodel the complex not fully defined\", \"CHIP recognition determinants not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the BRCT1 phosphate-binding pocket as the PAR-reading module that recruits XRCC1 to damage, defining the mechanism of PARP1-dependent recruitment.\",\n      \"evidence\": \"Pocket mutagenesis, PAR binding assays, live-cell laser recruitment, PARP1 Co-IP, survival assays\",\n      \"pmids\": [\"26130715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of PAR-pocket binding not resolved\", \"Relative contribution versus direct DNA binding not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established that XRCC1 loss causes PARP1 hyperactivation as the mechanistic driver of cerebellar neurodegeneration, providing a disease mechanism and therapeutic rationale.\",\n      \"evidence\": \"Patient fibroblasts and Xrcc1/Parp1 double-knockout mice with ADP-ribose, neuron counting, and ataxia readouts\",\n      \"pmids\": [\"28002403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger of PARP1 hyperactivation not yet defined at this stage\", \"Why cerebellum is selectively vulnerable unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a temporally required XRCC1 repair function in terminal muscle differentiation, extending its role to developmental contexts.\",\n      \"evidence\": \"Skeletal myoblast-specific Xrcc1 deletion, live foci imaging, perinatal lethality and myofiber histology\",\n      \"pmids\": [\"27462438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of caspase-triggered DNA breaks in differentiation not defined\", \"Whether the defect is BER-specific not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed CK2-dependent phosphorylation licenses PNKP recruitment but is dispensable for some XRCC1 repair, dissociating PNKP-dependent and -independent functions.\",\n      \"evidence\": \"Phosphorylation-mutant complementation in Xrcc1-/- fibroblasts, PNKP-GFP recruitment imaging, CPT/H2O2 survival\",\n      \"pmids\": [\"29100039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the PNKP-independent repair route not defined\", \"Why CPT hypersensitivity reverses with the mutant unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped a PNKP/DNA-binding region and showed cancer-associated R194W and R280H variants impair PNKP stimulation and recruitment, giving functional meaning to common polymorphisms.\",\n      \"evidence\": \"Domain binding and PNKP kinase assays with XRCC1 fragments; laser recruitment imaging of variants\",\n      \"pmids\": [\"30446622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cancer risk consequences in patients not tested here\", \"Structural basis of variant defects not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected chromatin state to XRCC1 recruitment by showing KDM5B-mediated H3K4 demethylation facilitates XRCC1 localization to damage and contributes to cisplatin resistance.\",\n      \"evidence\": \"KDM5B manipulation, Co-IP, XRCC1/\\u03b3H2AX co-localization, H3K4 methylation and pharmacological inhibition\",\n      \"pmids\": [\"29989047\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Link between demethylation and recruitment inferred from co-localization, not biochemically reconstituted\", \"Direct XRCC1\\u2013chromatin contact not demonstrated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined post-translational control of XRCC1 abundance, with SIRT1 deacetylation blocking \\u03b2-TrCP ubiquitination and a central DNA-binding domain governing retention versus repair rate.\",\n      \"evidence\": \"Co-IP, deacetylation-site mutagenesis, ubiquitination and half-life assays; CDB mutagenesis with in vitro binding and live-cell retention imaging\",\n      \"pmids\": [\"31043584\", \"30816207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How retention duration is normally set in vivo unclear\", \"Coupling of acetylation status to repair activity not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Uncovered a non-canonical XRCC1 role in alternative end-joining at stalled forks via a POLQ/MRE11 complex normally restrained by BRCA2, linking XRCC1 to replication-stress tolerance.\",\n      \"evidence\": \"In vitro alt-EJ reconstitution, Co-IP with POLQ/MRE11, BRCA2/XRCC1 co-depletion, fork restart and aberration assays\",\n      \"pmids\": [\"32776008\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab reconstitution in a novel pathway context\", \"In vivo significance of XRCC1-driven alt-EJ not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined XRCC1 as an anti-trapper that prevents PARP1 from becoming trapped on BER intermediates and showed aberrant PARP1 activity blocks transcriptional recovery via USP3, unifying the toxicity mechanism of XRCC1 loss.\",\n      \"evidence\": \"XRCC1-knockout cells, PARP1 trapping and BER accessibility assays, PARP1/USP3 deletion epistasis, histone ubiquitination and transcription recovery in neurons and patient fibroblasts\",\n      \"pmids\": [\"34102106\", \"34811483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of how XRCC1 displaces/limits PARP1 unresolved\", \"Generality of transcription-block mechanism across tissues not fully tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established a reciprocal recruitment dependency between PARP1 and XRCC1 and confirmed that PARP1 deletion partially rescues XRCC1-deficient repair and survival.\",\n      \"evidence\": \"PARP1/XRCC1 single and double KO HeLa cells, live recruitment imaging, NAD+, survival, and comet assays\",\n      \"pmids\": [\"35778544\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of the mutual recruitment dependency not resolved\", \"Only partial rescue indicates additional PARP1-independent defects\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural mechanism by which XRCC1 physically limits and displaces PARP1 on BER intermediates, and how its multiple recruitment cues (PAR, direct DNA, chromatin marks) are integrated, remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of an XRCC1-bound repair intermediate with PARP1\", \"Quantitative hierarchy among PAR-, DNA-, and chromatin-based recruitment unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [5, 17]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 3, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 18]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 17, 14]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [1, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 6, 11]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [10, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [\n      \"XRCC1\\u2013DNA ligase III\\u03b1 complex\",\n      \"XRCC1\\u2013Pol\\u03b2 heterodimer\",\n      \"XRCC1\\u2013POLQ\\u2013MRE11 alt-EJ complex\"\n    ],\n    \"partners\": [\n      \"LIG3\",\n      \"POLB\",\n      \"PNKP\",\n      \"PARP1\",\n      \"PCNA\",\n      \"POLQ\",\n      \"MRE11\",\n      \"HSP90\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}